Fecal microbiota transplantation as an effective therapeutic alternative
DOI:
https://doi.org/10.56294/shp2024145Keywords:
Clostridioides difficile, dysbiosis, pseudomembranous colitis, microbiota transplantation, therapeutic efficacyAbstract
Antibiotic-associated diarrhoea was a common complication of antimicrobial treatment, mainly caused by an imbalance in the gut microbiota. Clostridioides difficile was identified as the most frequent causative agent, capable of triggering pseudomembranous colitis, especially in vulnerable patients. Given the high recurrence rates of conventional treatments, faecal microbiota transplantation was evaluated as an effective therapeutic alternative. This procedure involved transferring faecal material from a healthy donor to an affected recipient, achieving remarkable restoration of intestinal balance, reduced mortality, and significant clinical improvement. In addition to its efficacy, a favourable safety profile and reduced healthcare costs were documented, consolidating it as a key tool in the treatment of recurrent C. difficile infections.
References
1. Martínez JV, Raush A, Efrón ED, Zubiaurre I, Pinoni MV, Giorgio PL, et al. Colitis refractaria por Clostridium difficile tratada con trasplante de microbiota fecal [Refractory colitis by Clostridium difficile treated with fecal microbiota transplant]. Medicina (B Aires). 2019;79(4):291–4. Spanish. PMID: 31487251.
2. Xu Q, Zhang S, Quan J, Wu Z, Gu S, Chen Y, et al. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model. Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6689–700. doi: 10.1007/s00253-022-12154-z. Epub 2022 Sep 10. PMID: 36085529.
3. Gupta K, Tappiti M, Nazir AM, Koganti B, Memon MS, Aslam Zahid MB, et al. Fecal Microbiota Transplant in Recurrent Clostridium difficile Infections: A Systematic Review. Cureus. 2022 May 5;14(5):e24754. doi: 10.7759/cureus.24754. PMID: 35693372; PMCID: PMC9174020.
4. Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther. 2019 Nov;50(10):1094–9. doi: 10.1111/apt.15526. Epub 2019 Oct 14. PMID: 31612528; PMCID: PMC6817391.
5. Health Quality Ontario. Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment. Ont Health Technol Assess Ser. 2016 Jul 1;16(17):1–69. PMID: 27516814; PMCID: PMC4973962.
6. Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2. PMID: 37096495; PMCID: PMC10125800.
7. Wilcox MH, McGovern BH, Hecht GA. The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis. Open Forum Infect Dis. 2020 Apr 11;7(5):ofaa114. doi: 10.1093/ofid/ofaa114. PMID: 32405509; PMCID: PMC7184446.
8. Dinleyici M, Vandenplas Y. Clostridium difficile Colitis Prevention and Treatment. Adv Exp Med Biol. 2019;1125:139–46. doi: 10.1007/5584_2018_322. PMID: 30689174.
9. Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver. 2019 Jan 15;13(1):16–24. doi: 10.5009/gnl18071. PMID: 30400734; PMCID: PMC6346998.
10. Cheng YW, Fischer M. Fecal Microbiota Transplantation: Redefining Surgical Management of Refractory Clostridium difficile Infection. Clin Colon Rectal Surg. 2020 Mar;33(2):92–7. doi: 10.1055/s-0040-1701233. Epub 2020 Feb 25. PMID: 32104162; PMCID: PMC7042019.
Published
Issue
Section
License
Copyright (c) 2024 Juliana Stupnik , Gerardo Laube (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
